Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Market Closed - Toronto S.E.
Other stock markets
 04:50:53 2024-07-05 pm EDT 		5-day change 1st Jan Change
2.21 CAD +4.74% Intraday chart for Medexus Pharmaceuticals Inc. +21.43% -10.53%
Jun. 26 Transcript : Medexus Pharmaceuticals Inc., Q4 2024 Earnings Call, Jun 26, 2024
Jun. 06 Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDA CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Medexus Pharmaceuticals Inc., Q4 2024 Earnings Call, Jun 26, 2024
Medexus Pharmaceuticals : Management Discussion & Analysis FY 2024
PU
Medexus Pharmaceuticals : Financial Statements FY 2024
PU
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
NE
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
NE
Medexus Pharmaceuticals - FDA Accepts for Review Treosulfan NDA Resubmission
AQ
Canadian Investment Regulatory Organization Trading Halt - MDP
AQ
Canadian Investment Regulatory Organization Trade Resumption - MDP
AQ
Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDA
CI
FDA Accepts for Review Treosulfan NDA Resubmission
NE
Federal Court Finds Patent For Concentrated Methotrexate Solutions Obvious
AQ
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
NE
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
NE
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients
AQ
Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)
CI
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
NE
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85
MT
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results
MT
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results
MT
Transcript : Medexus Pharmaceuticals Inc., Q3 2024 Earnings Call, Feb 08, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDP Stock
  4. News Medexus Pharmaceuticals Inc.